Pfizer Animal Health has launched Poulvac, the first modified live vaccine against E.coli in chickens.
The company claims that the vaccine, which can be used from one day of age, is set to bring major benefits in safeguarding the health of broilers, pullets for egg laying and breeding stock.
According to Pfizer, E.coli is one of the most significant bacterial pathogens found in chicks during the first week, leading to problems throughout the life of a flock including inferior performance, lack of uniformity and increased mortality. It is a costly, widespread problem for the UK poultry industry.
The vaccine was developed from research beginning in the 1990s at the Government's veterinary laboratories at Weybridge (now AHVLA) in the UK, employing genome technology to produce an avirulent strain of E.coli that induces protective immunity to the pathogenic strains of the bacteria.
The vaccine is completely non-pathogenic, and does not persist in the bird or the environment for any significant period of time. A gene deletion in its development restricts in vivo replication and leaves behind activated macrophages ready to respond to pathogenic E.coli strains.
Dr Stuart Andrews, poultry technical manager of Pfizer in the UK and Ireland said: "Poulvac E. coli provides broad cross protection against the key serotypes of E. coli infecting chickens. It is the only modified live, nonreactive vaccine proven to meet the European regulatory requirements for efficacy and safety.
"Trials have confirmed that Poulvac E.coli does not persist in the bird and proves to be self-limiting. The vaccine can survive in the environment for only a short time, and spread to in-contact birds is also limited."
The vaccine is administered as a coarse spray with onset of immunity 14 days afterwards and duration of immunity for up to 12 weeks. It can be used from day-old up to six weeks before the onset of lay, and has a nil day withdrawal period.
In the USA where Poulvac E coli has been available for six years field experience has shown the considerable benefits. In the Midwest where average layer mortality at 50 weeks of age was 2.31 per cent, this was reduced to 1.51 per cent with three doses of the vaccine*. In Eastern USA flock mortality compared with five previous flocks was reduced from over three per cent to one per cent.
A field trial in the USA with more than 300,000 broiler breeders vaccination before lay reduced mortality from 2.8 to 1.9 per cent - with only two out of 28 flocks needing antibiotic treatment compared with 13 of the 28 unvaccinated flocks.
On a broiler field trial in Georgia over four million birds were vaccinated with Poulvac E. coli at hatch. The vaccinated birds had a better feed conversion (1.79 against 1.84 for the controls) and with condemnations at the processing plant down from 1.22 to 0.73 per cent the result was a lower production cost of 0.51¢ per lb.
In another broiler trial covering more than two million birds in Arkansas livability was improved from 95.20 to 95.77 per cent and feed conversion improved from 1.95 to 1.90, gaining 0.45¢ per lb.
* Pfizer says it is important to note that in these studies carried out in the USA more than one dose of the vaccine was often administered. A single vaccination is licensed in the Summary of Product Characteristics however, where clinical disease requires and at the discretion of a veterinary surgeon, the vaccination schedule may be re-started as there is no contra-indication on the SPC.
Elanco has announced that it has finalised its acquisition of Novartis Animal Health.
The acquisition, announced in April last year, follows Elanco's purchase of Lohmann Animal Health earlier in 2014. It swells Elanco's portfolio to nearly 300 brands encompassing therapeutics, vaccines, parasiticides, antimicrobials, surgical, enzymes, food safety and more.
Gaynor Hillier, Elanco's General Manager UK and Ireland said: "Elanco's acquisition of Novartis Animal Health brings together two strong companies with a passion for serving the customer. We will continue to offer the products our customers trust, while significantly investing in the development of new solutions to meet our customers' greatest unmet needs."
The company says it will now increase investment in research and development significantly, with a combined portfolio of more than 100 product development projects focused on:
Gaynor added: "We'll continually seek innovative ways we can support our customers' business. With increased technical services, that combine our analytic and benchmarking tools with on-the-ground support, we'll be able to spend more time with individual customers seeking innovative solutions that can make a difference in their business."
Elanco says that the complete integration of the businesses will take some time, but it is trying to make the transition seamless. For the foreseeable future, business will continue in much the same way, including product ordering and customer support. Availability and access to products will continue uninterrupted.
For more information about the acquisition, visit www.elanco.com.
RSA has announced the rollout of its UK-wide network of preferred referral practices.
The scheme caused widespread concern within the profession when it was trialed in the Midlands earlier this year, primarily because of fears that it would reduce general practitioners' freedom to refer an animal to a centre that they felt could provide the most appropriate care for both the animal and the owner. In addition, RSA's claim that it was aiming to provide like-for-like care at a lower cost was undermined by the fact that the network could hardly field a single RCVS Recognised Specialist amongst its numbers. There were also concerns being voiced about the terms under which referral practices could join the network.
However, the underlying challenge of keeping pet insurance affordable remains. RSA says that according to its research, and based on Association of British Insurers averages, 27% of its customers pay more for their pet insurance than the average cost of home insurance; 17% pay more than the average cost of car insurance and 3% pay more than the average cost for private medical insurance.
It does seem as though RSA has been making a concerted effort to adopt a more collaborative approach before the nationwide rollout, having meetings with both the BVA and BSAVA which the respective organisations described as 'constructive'.
The current state of play is that RSA is inviting referral practices to join its network in advance of a launch some time after the end of the year. Thereafter, VetSurgeon.org understands that clients who decide to opt for a non-emergency referral outside its network will be subject to an additional flat fee which has yet to be announced.
Bill Paton, Claims Director for UK and Western Europe said: “The introduction of this new preferred referral network ensures that our customers will receive the most appropriate available treatment as diagnosed by their vet.
"For us, being able to control costs with our vet partners in the network will help us manage our claims cost more effectively and ensure that policy limits last as long as possible.
"Ultimately, this will have a positive effect on premium rates for our customers ensuring that pet insurance remains affordable.”
For more information about joining RSA's referral network, email: rsa.pet@uk.rsagroup.com.
The definition agreed by VN Council is as follows:
Veterinary nursing aims to ease the suffering and pain of animals, and to improve their health and welfare.
This includes providing any medical treatment or any minor surgery (not involving entry into a body cavity) to animals under the direction of a veterinary surgeon who has that animal under their care.
Veterinary nursing can be either proactive or reactive, and autonomous or collaborative. It is carried out in a wide variety of settings, for animals at all life stages, and considers the background and needs of the animal’s owner or keeper.
Matthew Rendle RVN, the Chair of VN Council, said: “Although it is just a few short lines, this definition of veterinary nursing has been in the pipeline for some time.
"While we as veterinary nurses have always been able to define ourselves by the type of tasks we carry out, or our relation to veterinary surgeons in terms of delegation, there hasn’t necessarily been a clear statement articulating the art and science of veterinary nursing.
“With the RCVS looking to expand its regulatory remit to include other veterinary paraprofessionals over the long term, we thought it was particularly important that we set out the stall for veterinary nursing and we hope that this clear statement will, in particular, aid the public in understanding the role of a veterinary nurse.
“It should be noted that this definition is VN Council’s own considered interpretation of the art and science of veterinary nursing.
"Other interpretations from other organisations, provided they conform with both Schedule 3 of the Veterinary Surgeons Act and the RCVS Code of Professional Conduct, could sit comfortably alongside ours, and we hope there continues to be healthy discussion about the contribution of the profession to the veterinary team, as our role evolves.”
They say this approach could lead to a reduction in the number of vaccines that need to be administered to each bird.
Vaccines that target multiple diseases are in high demand due to the many viruses that can circulate simultaneously in flocks. Protecting against the most dangerous diseases with one vaccine could reduce overall vaccination costs for poultry producers and decrease the number of times that birds need to be handled.
The researchers demonstrated that a gene editing system called CRISPR/cas9 can be used to insert a gene of the IBD virus into the currently used Marek’s disease vaccine virus. The added genetic material protects poultry against IBD in addition to the protection already offered by the Marek’s disease vaccine, meaning that bird owners would only need to use one vaccine instead of two.
Other vaccines generated by conventional methods can achieve a similar result, but by using the CRISPR/cas9 system the Pirbright researchers say they have been able to insert the IBD gene far more quickly, easily and accurately than the methods that have been used before. This will significantly reduce the time needed to generate new vaccines.
Professor Venugopal Nair, joint leader of the research at Pirbright said: "The method we have created with CRISPR/cas9 really increases the scope of how we edit the Marek’s disease vaccine to include other virus components. Now we have shown that the gene-edited vaccine protects against both Marek’s disease and IBD, we are looking at inserting more genes from other viruses."
The team intend to generate a vaccine that will be able to protect against multiple avian diseases and will next target two high consequence poultry viruses - avian influenza virus and the Newcastle disease virus. The flexibility of the new method also means that as the viruses evolve, the vaccine virus can be easily edited to include new genes which protect against emerging strains.
The Pirbright Institute says there has been huge commercial interest in using this technology to develop novel vaccines, so it intends to partner vaccine manufacturing companies to bring CRISPR/cas9 edited vaccines to market.
This scientific paper can be found in the Vaccine journal and was funded by the Biotechnology and Biological Sciences Research Council (BBSRC); grant numbers BB/P016472/1 BB/L014262/1.
Photo: Cells infected with the Marek's disease vaccine virus, HVT, (green) expressing the inserted infectious bursal disease virus gene, VP2 (red). Cell nuclei are shown in blue. © Dr Na Tang, The Pirbright Institute 2018.
Currently used by more than 200 practices and 50 universities around the world, the Equinosis Q is a diagnostic tool that can further aid the subjective lameness evaluation on all types of horses and ponies examined in the field or in hospital settings.
Christina Frigast, MRCVS, Eickemeyer Product Development Manager said: "The inertial sensors sample 20x faster than the human eye making the Equinosis Q a valuable tool to the veterinarian in the evaluation of subtle and multiple limb lameness.
"It does not interfere with the routine lameness examination as trot up on straight line, lunging and ridden evaluations can be performed on both hard and soft surfaces.
"Data is wirelessly streamed to a tablet PC and compiled into a reader-friendly report displaying the timing and severity of lameness. The effectiveness of diagnostic blocks can also be assessed with the Equinosis Q, providing the veterinarian with a percentage of improvement. In addition, comparison reports can be used to monitor rehabilitation progress."
Contact Eickemeyer to book a free demo, or for further information, visit: https://www.eickemeyer.co.uk/Diagnostics-and-Education/Anatomy-Models/Lameness-Locator-vet.html?listtype=search&searchparam=lameness
watch?v=MS6UXQSq6q0
During the 60 days before to 30 days after calving, dairy cows experience a dip in their natural immunity, leaving them especially vulnerable to important diseases such as mastitis2, metritis3 and retained placenta.4 With serious cost consequences and implications for cow welfare and productivity, this makes the transition period one of the most challenging yet vital periods for vets to manage with dairy clients.
Imrestor (pegbovigrastim injection) is a pegylated form of the naturally occurring protein cytokine, bovine Granulocyte Colony Stimulating Factor (bG-CSF). Elanco says it helps restore the cow’s natural defences by increasing the number and restoring the function of neutrophils, the primary type of white blood cell that recognizes and kills harmful bacteria.
Fiona Anderson, Technical Vet at Elanco, said: "It’s no secret that a successful transition period is vital for maximising productivity in the next lactation, yet we are still ‘firefighting’ common transition diseases like mastitis rather than focusing on their true cause."
"Vets are under increasing pressure to adopt a more proactive approach, not least to reduce the use of antibiotics in livestock but with few credible alternatives. This can be challenging in dairy herds, particularly around calving when cows are susceptible to multiple disease challenges while their defences are low. Imrestor helps to restore a cow’s own natural immunity and strengthen her ability to defend against infection by a range of mastitis pathogens – thus helping to protect the cow against mastitis when she needs it most."
Available in pre-filled, single-dose syringes, Imrestor is administered with two injections – one seven days prior to the anticipated date of calving and the other within 24 hours after calving – with neither injection requiring a withdrawal period.
Kingsley Baxendale, Ruminant Marketing Manager at Elanco Animal Health said: "It can be extremely frustrating for vets to see their dairy farmers struggling with the stress and hassle of dealing with increased numbers of sick cows during calving; they have enough to deal with at the moment. We’re delighted that Imrestor can provide vets with a tool to help decrease the negative consequences associated with immune-related diseases like mastitis and maximise their herds’ lactation potential."
As part of the launch of Imrestor, Elanco also announced its new 'Pledge To Protect' initiative to encourage vets and farmers to make a pledge symbolising their commitment to address immune suppression in their dairy cows.
The number of pledges will be tracked using a life-sized 2D cow model, pictured above. For each pledge, which can be made online or at events, Elanco will make a £5 donation to The Royal Agricultural Benevolent Institution (R.A.B.I), which supports farmers in difficulty. As a thank you for showing support, all pledgers will automatically be entered into a weekly prize draw.
To find out more about using Imrestor and how you can make your pledge, visit www.vital90days.co.uk.
References
Vetoquinol UK Ltd is launching a dedicated large animal/equine sales force on the 1st July.
The company says the move reflects the change in cattle and equine veterinary practice to become specialists.
Vetoquinol's large animal brands include: Marbocyl®, Sedalin®, Equistro®, Tolfine®, Pro Rumen and Locatim®.
The new team comprises:
The new sales team will be managed jointly by Hugh Gibson and Stuart Wade.
For further information or to make an appointment please contact your local Territory Manager direct or telephone 01280 825424
Norbrook Laboratories Ltd has launched a second generation Eprinomectin Pour On solution with zero milk withhold and a 10 day meat withdrawal period. Eprizero, for beef and dairy cattle, is indicated for the treatment and prevention of a range of economically damaging gutworm and lungworm infections and external parasites in a pour on application. It offers zero milk withhold and an improved meat withdrawal period of 10 days. Andrew Hillan MVB MRCVS, Director of Veterinary Science, Norbrook Laboratories Ltd., said: "Norbrook has launched Eprizero to offer vets and farmers a more versatile alternative in the treatment of economically damaging worms and external parasites. The active ingredient in Eprizero, Eprinomectin, is both potent and fast-acting and is supported by independent studies which show increased milk yield, improved fertility and increased dry matter intake following treatment. With a zero milk and 10 day meat withdrawal and waterproof properties, Eprizero offers real versatility to vets and farmers in terms of when and where they treat. It is this versatility that we believe will make Eprizero the gold standard in anthelmintic treatment for prolonged infestations of gut worm and lung worm in both dairy and beef cattle." Eprizero is available in four sizes - 250ml, 1L, 2.5L and 5L - with a free 75ml gun supplied with the two larger pack sizes. It is administered using a 75ml dispensing gun to enable accurate application. Eprizero is registered for use in the UK and Ireland and is available to order from your local Norbrook Sales Representative.
Vétoquinol has launched Flexadin, a new range of joint support products for cats and dogs with osteoarthritis (OA)
Robert Simpson, Flexadin Product Manager said: "This new range is made up of two products: Flexadin Plus and Flexadin Advanced, both are dietetic complementary feeds which are members of a small group of joint support products which contain Omega-3 fatty acids and Vitamin E. These ingredients are proven to aid the support of the metabolism of joints in the case of OA. Although many different joint support aids are available, not all of them contain these extra ingredients."
Vétoquinol says that in addition to Omega-3 fatty acids and Vitamin E, Flexadin Plus contains the traditional ingredients: glucosamine, chondroitin and devil's claw. Flexadin Advanced contains the novel ingredient, UCII - a type of undenatured type II collagen which has been manufactured using a patented process.
Flexadin Plus comes in two formulations, the first is specifically designed for cats/small dogs and the other is for medium/large dogs. Flexadin Advanced is specifically for dogs.
Robert added: "Flexadin Advanced has a specific property which means that the administration rate is only one chew per day whatever the weight of the dog. This has an important impact on the price per day for medium and large dogs which may require more than one tablet of traditional joint support products. This property also makes Flexadin Advanced a convenient option for owners. In addition to this benefit, UCII is becoming more and more popular due to the results of scientific studies in dogs, horses and even humans.
"We are all very excited about the advances this range can bring to veterinary practices."
Both Flexadin Plus and Advanced are presented as palatable, shaped, soft chews which come in zip-lock packs to keep the soft chews fresh and tasty. Flexadin Plus comes in packs of 90 chews whilst Flexadin Advanced comes in packs of 30 chews.
For further information about Flexadin, contact Vétoquinol on: 01280 825424.
Improve International has launched a new course for veterinary receptionists to achieve the nationally accredited Edexcel QCF Level 2 Certificate in Customer Service, but with the assessment tailored specifically to demonstrate excellence in veterinary client care.
Veterinary receptionists may be able to benefit from government funding to enable them to study for the qualification, which Improve says can be delivered either at its HQ in Swindon or in practice.
Government funding is available for students of the Certificate in Customer Service without an existing Level 2 qualification in another subject. Requests also depend on the age of the learner and will be assessed on an individual basis by Improve's local Edexcel accredited centre in Swindon.
The 30 hour course features three core units, assessed by a one hour online test:
David Babington MRCVS, founder of Improve International said: "A successful veterinary practice is no longer just about a 'good' vet or nurse. It's about a practice team pulling together and playing their role to the top of their ability. The key role played by receptionists in terms of creating that vital first impression and helping to maintain client loyalty cannot be understated and we wanted to offer them a form of training that would help them develop their skills while achieving a nationally recognised qualification. We look forward to welcoming our first students later this year."
For further information or to register, email enquiries@improve-international.com; visit www.improvecpd.com or call 01793 759159.
The briefing highlighted to members of both Houses the vital role the veterinary profession plays in order to ensure that the veterinary resource in clinical practice, public health, government services, academia and research is appropriately considered and effectively used during Brexit negotiations.
Lord Gardiner of Kimble, Parliamentary Under Secretary of State for the Department of Environment, Food and Rural Affairs (Defra), environment spokespeople for the Scottish National Party (SNP) and Plaid Cymru, and other parliamentarians from the Conservatives, Labour, Liberal Democrats, Plaid Cymru and the SNP, joined Crossbenchers, senior civil servants and key stakeholders at the event.
BVA President Gudrun Ravetz delivered a speech highlighting the main asks from the association's Brexit and the veterinary profession report, which was developed through consultation with BVA members, devolved branches, BVA specialist divisions and other key stakeholders.
The report sets out 52 recommendations for the short, medium and long term across seven areas of public policy: veterinary workforce, animal health, animal welfare, food hygiene and safety, veterinary medicines, research and development, and trade.
Addressing attendees, Gudrun said: "We are a relatively small profession, but we are a diverse profession with far-reaching influence and impact in so many areas of political and public life.
"Last week, we were delighted to hear the Defra Secretary of State, speaking to the Today programme, rightly acknowledged the importance of EU vets to the UK economy; from food hygiene and safety, to monitoring disease outbreaks and facilitating trade. This is why BVA is calling on the Government to guarantee the working rights for non-UK EU vets and vet nurses currently working and studying in the UK at the existing level and with no time limit.
"As we progress with the Repeal Bill we are also calling on the Government to ensure we maintain animal health and welfare current standards – and prioritise them in all trade negotiations, so that high standards of animal health, welfare and food hygiene are a unique selling point for the UK. We can only make a success of Brexit if we harness our veterinary resource."
In his speech, RCVS Junior Vice-President Professor Stephen May highlighted the three RCVS Brexit Principles as well as the findings from the College’s recent survey of non-UK EU vets working in the UK. Professor May also made a call for greater certainty from the Government on the status of EU citizens living and working as veterinary surgeons in the UK and for a substantial transition period to prevent potential veterinary workforce shortages, particularly in areas such as public health and food safety.
Professor May said: "Negotiations with our European partners will no doubt be lengthy and complex on all manner of issues that affect the veterinary sector. For everyone concerned, we join other voices in calling for a substantial transition period to any new order created. This will provide us with time to take stock, to understand the implications and to navigate a pathway that safeguards the interests of our sector and the RCVS is determined to work with all its stakeholders, in particular Government and yourselves [parliamentarians], to ensure that vital veterinary work gets done.
"Key to this will be meeting the need for high-quality, capable veterinary surgeons in all sectors. This can only be achieved in the short-term by emphasising the continued welcome and appreciation of all veterinary non-UK nationals working hard for this country, to encourage them to stay, and continued access to graduates of accredited schools from around the world, alongside increased training of UK nationals to meet our ever expanding veterinary needs."
The event was hosted by BVA Honorary Member and RCVS Past-President, Lord Trees MRCVS, who has sat on a number of House of Lords committees and subcommittees that consider and seek to influence the Government’s plans and policy-making during the UK’s exit from the EU.
Lord Trees closed the BVA and RCVS Brexit briefing by encouraging fellow Peers and MPs to capitalise on the evidence-based, science-led perspective that the veterinary profession is able to provide, particularly as Brexit discussions continue to develop.
Lord Gardiner has since publicly recognised the vital role of the veterinary profession, responding to a question in the House of Lords regarding the retention of skilled workers post-Brexit. In his role as Defra Parliamentary Under Secretary of State, Lord Gardiner said:
"I am most grateful to the noble Lord [Teverson] because I was at the BVA and RCVS reception yesterday, where I know a number of noble Lords were also in attendance. This is an important issue and an element of the negotiations that we want to deal with as promptly as possible. Yes, we do rely on and warmly welcome the support we have from EU national vets, who are hugely important to us."
Richard Malik from the Centre for Veterinary Education at the University of Sydney and Mike Lappin from Colorado State University, known for their amusing and questioning presentations, will be joined by experts including Jayne Sykes, Séverine Tasker, Donato Traversa and Francesca Mancianti to present the latest information about the diagnosis and treatment of a veritable smorgasbord of feline infectious diseases, including heartworm, leishmaniasis, toxocara, aspergillus, bartonella, coronavirus, erlichia, anaplasma, rickettsia, lungworm, mycobacteria, FeLV, FIV, haemoplasmas, cryptococcosis, GI disease and emerging feline pathogens.
Together with a mini-symposia organised by the congress sponsors – Idexx, Hill’s, Ceva, Bayer and Boehringer Ingelheim – the five-day event is worth 25 hours of feline CPD.
If you need more in-depth knowledge of feline infectious diseases, there are also three masterclasses planned.
The venue looks drop-dead gorgeous too. Set on a small wooded peninsula embraced by two harbours, Cavtat has a pretty waterfront peppered with restaurants, pebbly beaches and an interesting assortment of artsy attractions, making it one of the most desirable tourist destinations in the region. ISFM says it's a great base from which to explore Dubrovnik and the surrounding area.
The welcome party will take place at the congress hotel’s waterfront restaurant on Thursday evening.
Tickets cost £475 for ISFM members and £605 for non-members. Masterclasses are an additional £50 each.
That seems like an absolute steal to me, and I'm not even a vet. Where do I sign?
Ah, here it is: https://icatcare.org/isfm-congress
CEVA Animal Health has launched the anti-inflammatory Meloxidyl for cattle and pigs.
Meloxidyl is meloxicam-based solution for the management of respiratory disease, mastitis and diarrhoea in cattle and non-infectious locomotor disorders and puerperal septicaemia and toxaemia in pigs. It is given via a single injection, when used in combination with suitable anti-infectives.
According to the company, Meloxidyl's one shot protocol means it is quick and economical to use; it allows control of inflammation and endotoxins and reduces somatic cell count, recovery time and risk of culling after clinical mastitis; it reduces the economical impact of respiratory signs in comparison with flunixin-based products and reduces the major clinical signs caused by toxins in cases of neonatal diarrhoea.
Meloxidyl can be used in combination with the company's range of anti-infectives, which includes Marbokem, Cevaxel and Florkem.
For further product information contact CEVA Animal Health Ltd, 90 The Broadway, Chesham, Bucks, HP5 1EG, telephone 01494 781510 or visit the website at http://www.ceva.uk.com/
The company, which now has over 20,000 monthly subscribers in the UK, saw a massive growth during the pandemic, with a reported 1000% increase in monthly recurring revenue over the past two years.
Since March 2020, VetBox has shipped over quarter-of-a-million boxes.
Bought by Many says the acquisition is a major part of its expansion beyond insurance and into preventative wellness.
Will said: "I founded VetBox after seeing that far too many UK pets were missing out on essential parasite protection.
"I'm really proud of the progress that VetBox has made in solving this issue in just five years and can't wait to see what we can achieve as part of the Bought By Many family.
"As a vet I've seen first-hand the fantastic service Bought By Many offer pet owners, so it's been a pleasure seeing this partnership grow over the past few years."
The outbreak, which was widely covered in the media, caused concern amongst cat owners.
The findings of an investigation found a link between high concentrations of trichothecene T-2/HT-2 mycotoxins (both poisonous substances, produced by fungi) in certain cat foods.
The first study, published in the Journal of Veterinary Internal Medicine, describes 580 cats recorded by the RVC’s database during the initial outbreak, the epidemiology of the cases and the link with mycotoxin exposure.
The cats presented with severe reductions in vital blood cells, including white blood cells responsible for fighting infection and platelets responsible for blood clotting.
The research recounts how analysis of these cats’ data – provided both by pet owners and vets - revealed three diets that had been consumed by the majority of affected cats and how this subsequently led to a UK wide recall in June 2021.
Examining the subsequent analysis of the feed samples and the discovery of mycotoxin contamination, which is known to be toxic to bone marrow, and thereby negatively impacting the production of key blood cells, the study concludes that mycotoxin contamination should be considered as the cause of the outbreak.
The second study examines 50 cats identified as having pancytopenia in more depth, providing a detailed picture of clinical findings to better understand the disease process in these cats affected by the outbreak.
Records and data of 50 of the affected cats were assessed to identify additional clinical signs which indicated contact with mycotoxins.
Following examination of the cats’ bone marrow, it was found that all cats suffered a marked toxic insult to their bone marrow.
From this, the study concluded that a differential diagnosis of mycotoxin-induced pancytopenia should be considered in cats presenting with pancytopenia.
Lead author of the research, Dr Barbara Glanemann, Senior Lecturer in Small Animal Medicine at the Royal Veterinary College and Co-head of the Small Animal Internal Medicine Service at the RVC’s Queen Mother Hospital for Animals, said:
“These pieces of research involved a great deal of work from many people (noted as authors and acknowledgements in the papers) and we really appreciate the teamwork involved, and the collaborative support we received.
“We know first-hand how much devastation and concern this outbreak caused for many cat owners across the country and so it is our hope that the studies will help people better understand what happened to cause this outbreak and can be used to not only provide some closure to those affected but also reduce the chances of something similar occurring in the future.”
In response to the question ‘How important is sustainability to you personally?’, 57% of respondents said it was very important making it the most popular choice.
However, in answer to the question: ‘Is your practice team actively working to improve sustainability?’, 20% of respondents said ‘Always/wherever possible’ and 42% said ‘Most of the time’, leaving 38% not actively working to improve sustainability.
IVC says the conclusion to be drawn is that sustainability is a personal priority, but this isn’t always translating to practice and more can be done.
To help with this, the company will shortly Positive Hoofprint, an Equine and Farm specific toolkit to help practices become more sustainable, with resources, checklists and practical advice for prioritising environmentally friendly initiatives.
Mark Tabachnik, UK Head of Equine for IVC Evidensia, said: “It’s clear from our survey that sustainability is still being treated as a secondary concern in practice, and this is something that IVC Evidensia is actively seeking to change.
“With our Positive Hoofprint about to be launched, there has never been a better time to prioritise our sustainability goals and to embed them in our own practices.
“This will give colleagues the tools they need to care for the planet, so we can fundamentally change equine veterinary to be more environmentally conscious for the future.”
Further investigation revealed that the products in question: AVA Mature Cat Chicken 2kg, AVA Mature Cat Chicken 4kg, AVA Senior Cat Chicken 2kg and AVA Adult Cat Neutered Indoor 1.5kg, all had insufficient levels of thiamine (vitamin B1), which caused the cats to exhibit symptoms of sudden collapse, fitting, widespread twitching and general unsteadiness.
Talking to the BBC, Pets at Home spokesperson Brian Hudspith said it was important to alert veterinary surgeons as well as customers because thiamine deficient cats would usually present with quite different symptoms, including stiff limbs and the head falling onto the sternum.
He said: "Rather than the more typical cervical ventroflexion (head falling onto the chest) associated with thiamine deficiency, in the three cases we saw the predominant clinical signs included sudden collapse, fitting, widespread twitching and general unsteadiness on their legs, which began suddenly after 4-6 weeks of being on the diet."
Pet owners who have bought the products are being advised by the company to dispose of the contents and return the packaging to any Pets at Home store for a full refund. Owners who think their cat is demonstrating any of the symptoms are being advised to seek immediate veterinary advice, and to contact the company's customer advisors on 0800 328 4204.
IMPORTANT UPDATEDavies Veterinary Specialists has published advice and support for veterinary professionals and pet owners concerning the diagnosis and treatment of thiamine deficiency in cats, here.
Eggshell membrane is rich in proteins and contains collagen type I, hyaluronic acid, chondroitin sulphate and glucosamine. Virbac says the components of eggshell membrane help to limit inflammatory processes that occur in osteoarthritis and preserve the existing cartilage structure whilst promoting synthesis. The company points to a study which showed that eggshell membrane contributes to a reduction in pain perception by 25%, improved joint function by 33% and increased quality of life by 35% within 6 weeks1.
Rémi Mandray, Product Manager at Virbac said: "I am delighted to be able to introduce this innovative new ingredient to the Veterinary HPM Joint & Mobility Clinical Diet. This is an addition to an already very comprehensive approach to nutrition in dogs with osteoarthritis, which affects 20% of the adult canine population2. Studies have shown that improvement on mobility is visible as quickly as 2 weeks after diet introduction3 – changing their diet truly can change their life!’
For more information contact your Virbac Territory Manager.
Reference
The new formula also contains crataegus, L-carnitine and magnesium taurate, and is designed to be used alongside all heart medications.
Alongside the launch of the new product, Vita has also created an infographic highlighting the common signs of heart disease in dogs.
https://vitaanimalhealth.com/common-signs-of-heart-disease
https://vitaanimalhealth.com/product/omnicardio-plus
Norbrook Laboratories Ltd has relaunched its website with a focus on veterinary technical support, farmers and pet owners, and a new online recruitment system.
The new site has sections dedicated specifically to farm animal, equine and pet healthcare. Norbrook says each section will feature articles and information on relevant issues in addition to help and support for the company's animal health pharmaceutical product ranges.
Alanna Carty, European Marketing Director said: "Animal Healthcare is a massive area within which there are a range of very different users and requirements. On our new website, we have categorised three specific groups - Farm Animals, Horses and small companion animals or pets. Users can now easily navigate directly to the specific area they are interested in and obtain the information they need in an instant. In addition, we have included articles and information on relevant topics eg Bovine Respiratory Disease or Arthritis in cats and dogs which will help animal health carers to keep abreast of key issues in what is a fast-changing environment"
The new site also incorporates a Veterinary Technical Support section dedicated to veterinary surgeons, veterinary nurses and practice managers. Alanna said: "Time is a precious commodity for veterinary surgeons and nurses. They need information on drugs and treatments as quickly as possible and our new website has been designed to meet this need. Our quick search allows vets and assistants to quickly identify products they may wish to use and our full Product Compendium is also available online."
The site also includes a new online recruitment section which aims to streamline the process for the 3000 or so applications the company currently receives each year.
Mrs Louise Kirk, Head of Personnel said: "The beauty of the online recruitment system is that it makes life easier for everyone involved in the process. Applicants have more time to complete the application form because they can begin online as soon as they become aware of the advertised position. They can begin to complete the form, save it and return to it or amend it until they are happy to submit it, at which point they receive a confirmation email and a pdf copy of their application form. However the system also allows for the form to be downloaded and posted to applicants who are unable to use the online system."
www.norbrook.com
Virbac Animal Health has launched a broad spectrum wormer for dogs called Endogard (praziquantel, pyrantel and febantel).
Virbac says Endogard offers treatment against most types of intestinal worms found commonly in dogs. It is presented in two tablet sizes for easy dosage.
Victoria Hudson, Product Manager for Endo and Ectoparasiticides, said: "While we're known for developing innovative products which help practices generate additional revenue streams, we can also support them by offering cost-effective and proven products for routine use.
Endogard is a perfect example. The efficacy of its active ingredients is well-established; it's simple for owners to administer and it's also affordable which will bring them back to the practice. It's an excellent addition to Virbac's strong range of parasite control treatments."
For further information, contact your Territory Manager or call Virbac on 01359 243243.
For the study, Tim Charlesworth, an RCVS Specialist in Small Animal Surgery from Eastcott Referrals (pictured right), analysed 260 cases where dogs had undergone laparoscopic or open surgical ovariectomy between January 2013 and January 2018 by the same team of similarly experienced surgeons using standard practice anaesthetic, theatre and perioperative protocols. Complications were then compared between the two groups.
44% (46) of the dogs that underwent open ovariectomy developed a complication, compared to 20% (31) of those that underwent laparoscopic ovariectomy.
Whilst the authors acknowledge the limitations of a retrospective study and emphasise that confirmation requires a randomised trial, they say that when considered alongside previously demonstrated improved postoperative comfort and earlier return to normal function, laparoscopy could be considered preferable for ovariectomy in dogs.
The campaign uses Pennies, the digital charitable giving system which invites you to make a small donation when you pay for something by debit or credit card.
For the last four years, Medivet clients have been invited to make a donation of 50p when paying their veterinary bill, and the millionth donation was made at Medivet 24 Hour Shrewsbury this week.
Medivet says the funds raised have played a crucial role in helping to protect the rhino - enabling Wilderness Foundation Africa's Forever Wild Rhino Protection Initiative to support these critically endangered species across a wide range of activities. This includes the treatment of poaching attack survivors plus the care and rehabilitation of orphaned baby rhinos.
In terms of prevention, thanks to Medivet client donations, two cold scent tracker dogs have been deployed – Ella and Ziggy – who work with anti-poaching units, while support has also been provided for intelligence-sharing amongst local law-enforcement agencies. Funds have additionally been deployed to help drive global awareness, provide community services as well as essential field-based veterinary equipment.
Dr John Smithers, Senior Partner and Project Co-ordinator for Medivet Saving the Rhino, said: "We could not be more grateful to our clients for all they have done to help the survival of this iconic species. Their incredible generosity - combined with the support of our colleagues and partners - has made a real difference in the fight against poaching and we want to thank our clients for every donation made."
In South Africa, the Medivet-supported efforts to reduce poaching are co-ordinated by Dr William Fowlds, a former Medivet employee, who added: "This is a truly remarkable milestone and we are overwhelmed by the kindness of Medivet and its clients. The money raised not only helps protect the rhinos but helps bring to justice those responsible for the destruction of these precious and innocent creatures."
Alison Hutchinson, CBE, CEO of Pennies said reaching 1m donations was a remarkable achievement: “Pennies is proud to support Medivet’s Saving the Rhino campaign, and it’s been so inspiring to see one million individual micro-donations made through the digital charity box over the past four years.
"From all at Pennies, thank you and congratulations to the Medivet team and their hugely generous clients for reaching this milestone, for challenging the rhino poaching crisis in South Africa, and proving that small change truly does add up to mean big things."
Three cheers from VetSurgeon.org, too. That's a big achievement by Medivet for an important cause.
The RCVS Disciplinary Committee has dismissed an application for restoration to the RCVS Register from Dr Janos Nemeth, who was struck off in 2009 for fraudulent registration.
This was Dr Nemeth's second unsuccessful restoration application, and the Committee said it would hear no further application unless the Committee Chairman, advised by the Legal Assessor, considered it to have a reasonable prospect of success.
At the original hearing on the 23rd February 2009, Dr Nemeth, who had practised in the Wokingham area of Berkshire, was found to have dishonestly entered his name in the RCVS Register. Although he held a veterinary science degree from the Szent István University in Budapest, he had included a forged document in his registration application. He lodged an appeal with the Privy Council the following month, but did not pursue it; the appeal was dismissed in September 2009 and his name was removed from the Register. Dr Nemeth was ordered to pay costs of £8,904.59, which remain outstanding.
In September 2010, he applied to the RCVS Disciplinary Committee for restoration of his name to the RCVS Register, denying that he had produced a fraudulent document. In refusing the application, the then-Committee told Dr Nemeth that it had no appellate jurisdiction and that the onus was on him to demonstrate that he was a fit and proper person, before his name could be restored. It advised him generally about a future application for restoration.
At this week's restoration hearing, Dr Nemeth told the Committee that he did accept the original findings of the Committee but, at the same time, told them again that he was not party to the forgery. He also said that he held a licence to practise from the Hungarian Veterinary Chamber, and had been employed since October 2011 as a veterinary surgeon in a small animal hospital in Budapest, where he carried out a wide range of work including surgery. He also said he had attended two CPD courses.
The Committee accepted this. However, it continued to be concerned about the absence of evidence. Dr Nemeth had not produced evidence of CPD undertaken or provided letters of support from employers or colleagues, to give comfort to the assertion that he should be permitted to practise in the UK. The Committee rejected Dr Nemeth's argument that his licence to practise in Hungary meant he did not need to do this.
Committee Chairman Professor Peter Lees said: "The Committee is disappointed by Dr Nemeth's continuing lack of insight and is satisfied that he has paid insufficient attention to the guidance given at the previous restoration hearing. The burden remains on him to satisfy this Committee that he is a fit and proper person, before his name can be restored to the Register."
The application was dismissed.